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ABSTRACT
Objective: To understand general practitioners’ (GPs)
use of individual risk factors (blood pressure and
cholesterol levels) versus absolute risk in
cardiovascular disease (CVD) risk management
decision-making.
Design: Randomised experiment. Absolute risk,
systolic blood pressure (SBP), cholesterol ratio (total
cholesterol/high-density lipoprotein (TC/HDL)) and age
were systematically varied in hypothetical cases. High
absolute risk was defined as 5-year risk of a
cardiovascular event >15%, high blood pressure levels
varied between SBP 147 and 179 mm Hg and high
cholesterol (TC/HDL ratio) between 6.5 and 7.2 mmol/L.
Setting: 4 GP conferences in Australia.
Participants: 144 Australian GPs.
Outcomes: GPs indicated whether they would
prescribe cholesterol and/or blood pressure lowering
medication. Analyses involved logistic regression.
Results: For patients with high blood pressure: 93%
(95% CI 86% to 96%) of high absolute risk patients and
83% (95% CI 76% to 88%) of lower absolute risk
patients were prescribed blood pressure medication.
Conversely, 30% (95% CI 25% to 36%) of lower blood
pressure patients were prescribed blood pressure
medication if absolute risk was high and 4% (95% CI 3%
to 5%) if lower. 69% of high cholesterol/high absolute
risk patients were prescribed cholesterol medication
(95% CI 61% to 77%) versus 34% of high cholesterol/
lower absolute risk patients (95% CI 28% to 41%). 36%
of patients with lower cholesterol (95% CI 30% to 43%)
were prescribed cholesterol medication if absolute risk
was high versus 10% if lower (95% CI 8% to 13%).
Conclusions: GPs’ decision-making was more
consistent with the management of individual risk factors
than an absolute risk approach, especially when
prescribing blood pressure medication. The results
suggest medical treatment of lower risk patients (5-year
risk of CVD event <15%) with mildly elevated blood
pressure or cholesterol levels is likely to occur even when
an absolute risk assessment is specifically provided. The
results indicate a need for improving uptake of absolute
risk guidelines and GP understanding of the rationale for
using absolute risk.
INTRODUCTION
International guidelines for cardiovascular
disease (CVD) prevention encourage the use
of absolute risk to guide treatment with
blood pressure and cholesterol lowering
medication.1–6 Several risk prediction models
exist that differ in the duration over which
they calculate CVD risk (typically 5 or
10 years) and the variables they base the risk
on.7 8 One of the most commonly used
Strengths and limitations of this study
▪ This study uses a rigorous experimental design
to systematically investigate how general practi-
tioners’ (GPs) use individual risk factors (blood
pressure and cholesterol) versus the absolute
risk of a cardiovascular disease (CVD) event in
their decision-making about CVD preventive
medication. International guidelines are based on
absolute risk, but are used inconsistently.
▪ The results show that GPs’ decision-making was
more consistent with management of individual
risk factors than an absolute risk approach,
especially when prescribing blood pressure low-
ering medication.
▪ Our findings have important clinical implications,
suggesting that medical treatment of lower risk
patients (5-year risk of CVD event <15%) with
mildly elevated blood pressure or cholesterol is
likely to occur even when an absolute risk
assessment is specifically provided to GPs.
▪ The results may over-estimate the use of abso-
lute risk in clinical practice due to: (1) a low
response rate that is typical of such GP studies
but may have favoured those more interested
and positive about absolute risk, (2) reliance on
self-reported intentions, which was necessary to
enable an experimental design and (3) explicitly
providing GPs with an absolute risk score for
each case, since absolute risk is often not
assessed in practice.
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absolute risk models is the Framingham risk equation
(FRE),9 which estimates the risk of a cardiovascular
event based on sex, age, smoking status, diabetes, systolic
blood pressure (SBP) and cholesterol ratio. The
Australian guidelines classify patients with a 5-year risk of
>15% as high risk and recommend that they should be
simultaneously treated with cholesterol and blood pres-
sure lowering medication in addition to lifestyle inter-
vention unless contraindicated or clinically
inappropriate.10 11 For lower risk patients ≤ 15% without
additional risk factors such as family history, lifestyle
intervention is recommended as the primary manage-
ment approach. Adults with very high individual risk
factors (SBP ≥180 or diastolic blood pressure
≥110 mm Hg or total cholesterol >7.5 mmol/L) do not
require absolute CVD risk assessment because they are
already considered to be at high risk of CVD.10 11
Using absolute risk is a major shift from the traditional
approach of treating high blood pressure and high chol-
esterol individually. An absolute risk approach is likely to
achieve the best balance between preventing CVD events
and avoiding unnecessary treatment with medication. It
has the potential to reduce overtreatment of people who
have an elevated individual risk factor (eg, blood pres-
sure) but low or moderate overall risk of a CVD event
and reducing under treatment of people with slightly
elevated individual risk factors but a combined high
overall risk.12 13 The ﬁrst FRE was published in 197614
and New Zealand was the ﬁrst country to introduce an
absolute risk approach in 1993.15 More than 20 years
have passed since then and the absolute risk approach
has been shown to reduce short-term CVD risk without
causing clinical harms.14
However, research suggests that general practitioners
(GPs) often do not use absolute risk to guide their
decision-making about CVD prevention.15–19 Past
research includes studies exploring barriers to GPs’ use
of absolute risk19–22 and studies quantifying treatment
gaps using clinical databases12 16 17 23 24 but individual
decision-making about absolute risk has not been com-
prehensively examined quantitatively. In this study we
applied a method based on judgements of hypothetical
patient cases to analyse GPs’ decisions about CVD risk
management and their use of absolute risk.
Hypothetical patient cases (also called vignettes) have
been widely used to measure decision processes in a
range of clinical settings,25 including GP decision-
making about CVD.26–28 Indeed, three recent studies
using patient cases suggest that clinicians might not base
treatment decisions on absolute risk thresholds (eg, only
treat patients >15% for 5-year FRE based absolute risk or
>20% for 10-year risk); instead they focus on the levels
of the individual risk factors blood pressure and choles-
terol.26–28 However, these studies did not systematically
assess different combinations of absolute risk and indi-
vidual risk factor levels. Therefore, they provide limited
interpretation of how GPs use absolute risk versus indi-
vidual risk factors in decision-making.
In the current study we used hypothetical patient
cases (from here on referred to as cases) in which the
levels of absolute risk and three individual risk factors
(SBP, cholesterol ratio (total cholesterol/high-density
lipoprotein (TC/HDL), and age) were systematically
varied in order to evaluate their respective inﬂuence on
GPs’ decision-making about CVD risk management.
Absolute risk levels were derived from the FRE.9
In line with the literature suggesting that GPs tend to
use an individual risk factor approach, we hypothesised
that:
1. GPs are more likely to treat lower absolute risk with
medication when individual risk factors (blood pres-
sure, cholesterol) are higher than when individual
risk factors are lower; and conversely;
2. GPs are less likely to treat high absolute risk with
medication when individual risk factors (blood pres-
sure, cholesterol) are lower than when individual risk
factors are higher.
METHOD
Recruitment
GPs currently practicing in Australia were recruited
between May and November 2012 at four general prac-
tice conferences in New South Wales, Victoria and
Queensland. All participants were asked when they
became a GP and whether they were currently practicing
in Australia through survey questions, and the eligibility
of returned questionnaires was veriﬁed before data
analysis.
Data collection and measurement
Respondents viewed a generic patient scenario (see box 1)
followed by a table with the relevant values for absolute
risk, SBP, TC/HDL ratio, HDL, total cholesterol and age,
as well as patient gender and smoking status (ie, the
cases). GPs were asked how they would manage the
patient in the case: prescribe cholesterol medication, pre-
scribe blood pressure medication and/or prescribe aspirin
(yes/no for each). In addition, they were asked when they
would reassess the patient (open ended). The aspirin and
reassessment results are reported separately. We collected
Box 1 General patient scenario
“A regular patient of yours presents for a ‘check-up’ and has no
current symptoms. He/she has been trying to improve their diet
and increase their physical activity levels. You have several previ-
ous blood pressure readings at approximately the same level as
observed today. A recent test of electrolytes, liver function and
renal function was normal.”
BMI: 27
Medical history: nil of note
Family history: mother died of bowel cancer, nil family history of
ischaemic heart disease
Social history: married, lives in own home
Ethnicity: Caucasian
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information regarding GP characteristics: gender, age,
years in practice, practice size. We asked GPs two questions
about their use of absolute risk as follows: ‘For the cases
you just read, how often did you use the absolute risk score
to inform your management decision?’ and ‘In your
general practice, how often do you use absolute risk
scores, calculators or charts when assessing a patient’s level
of cardiovascular risk?’ (5-point Likert scale; 1 never—5
always). The survey was piloted with nine GPs.
Different sets of cases
We developed four sets of cases (also see table 1):
Ai. High IR (individual risk)/lower AR (absolute risk)
with high individual risk factors (blood pressure only)
and lower absolute risk;
Aii. High IR/lower AR with high individual risk factors
(cholesterol only) and lower absolute risk;
B. High IR/high AR with high individual risk factors
and high absolute risk;
C. Lower IR/high AR with lower individual risk factors
and high absolute risk;
D. Lower IR/lower AR with lower individual risk factors
and lower absolute risk.
Cases were designed to be clinically plausible and rele-
vant. Only the sets of cases B and C were eligible for
treatment with cholesterol and blood pressure lowering
medication according to the Australian absolute risk
guidelines.10 11 In all cases except high IR/lower AR (Ai
and Aii) the levels of individual risk factors were the
same across blood pressure and cholesterol (ie, both
lower or both high). For cases with high IR/lower AR
(Ai and Aii) blood pressure was high and cholesterol
was lower, or vice versa, to enable exploration of their
independent effects on GP decision-making. This
resulted in a core set of 25 cases with different combina-
tions of absolute and individual risk factor levels (see
online supplementary appendix 1 for the complete set
of cases).
Gender and smoking status
We constructed a female and male equivalent of each
core case (where possible, given the restraints of the
FRE and the individual and absolute risk levels deﬁned
above). We made all high absolute risk cases smokers
and all lower absolute risk cases non-smokers, and we
constructed an additional set of cases to test for the
potential confounding effect of smoking.
Levels of absolute risk and individual risk factor levels
The levels used to describe elevated absolute risk and
the individual risk factors (see table 1) were based on
the 2012 Australian absolute risk guidelines11 (using the
FRE) and informed by practicing GPs ( JD and PG). We
deﬁned patients with a risk of a cardiovascular event
over 5 years greater than 15% as high absolute risk, for
whom preventive medication is recommended. The
Australian absolute risk guidelines recommend that
adults with SBP ≥180 mm Hg or total cholesterol
>7.5 mmol/L do not require absolute CVD risk assess-
ment because they are already known to be at clinically
determined high risk of CVD.5 11 We ensured that the
individual risk factor levels remained below these thresh-
olds and, where possible, we avoided values that were
close to the cut-off. High blood pressure levels varied
between SBP 147 and 179 mm Hg and high cholesterol
(TC/HDL ratio) between 6.5 and 7.2 mmol/L. Lower
blood pressure levels varied between SBP of 110 and
145 mm Hg and lower TC/HDL ratio between 3 and
6 mmol/L. We deﬁned three age categories within the
target population for CVD risk assessment: 47, 61 and
72 years. Previous Australian guidelines for cholesterol
(2005)29 and hypertension management (2010)30 are
consistent with the 2012 guidelines recommendations
for the commencement of cholesterol lowering and/or
blood pressure lowering drug treatment in patients with
an absolute risk >15% of a CVD event in the next
5 years, or those with an absolute risk of 10–15% with
the presence of additional risk factors but have now
been replaced with the 2012 guidelines.
Randomisation
There were 25 core cases with systematically varied levels
of absolute risk, cholesterol, blood pressure and age.
Each case had between one and three versions to enable
male/female and smoking/non-smoking comparisons,
depending on clinical plausibility. Eleven of the core
cases were randomly selected for each survey to reduce
response burden, and only one version of the selected
case was used (eg, only the female, non-smoking
version). The 11 selected cases were presented in
random order. This process generated a total of 43 clin-
ically possible cases (see online supplementary appendix
1 for details of each case).
Analysis
GPs’ decisions on risk management for the different
cases were summarised as the percentage of cases in
which the GPs would prescribe cholesterol or blood pres-
sure lowering medication. We analysed how the chances
of prescribing medication changed according to the risk
proﬁles of the cases (ie, levels of absolute and individual
risk factors). This was done using generalised estimation
equations (GEEs) with a logit link (logistic regression)
and an exchangeable working correlation matrix to take
into account the clustering of cases per GP.
The outcome was whether the GP would prescribe
medication for the case, and the covariates were the
levels of absolute risk and individual risk factors (ie,
blood pressure and cholesterol levels) presented in the
cases. More speciﬁcally, four sets of cases were com-
pared: (A) high individual risk factors and lower abso-
lute risk, (B) high individual risk factors and high
absolute risk, (C) lower individual risk factors and high
absolute risk and (D) lower individual risk factors and
lower absolute risk. The 95% CIs for the percentages
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presented in the results section and ﬁgure 2 were
obtained from the GEEs.
We performed exploratory analyses to examine (1)
how risk management changed according to GP
characteristics (ie, age, gender, years in practice, practice
size and self-reported use of absolute risk in practice
and in the cases) and (2) how risk management
changed according to speciﬁc characteristics of the cases
presented (ie, age, gender and smoking status). This was
achieved by testing the interaction between each charac-
teristic and the four sets of cases with different risk pro-
ﬁles in separate GEEs (one for each characteristic). The
statistical analysis was performed with the software SPSS
V.21.
Missing data handling
Five participants completed only half of the survey
(1 out of 2 pages). For those participants, only the com-
pleted part of the survey was included in the analysis. In
addition, there was an average of ﬁve missing responses
per case. In most instances the missing values occurred
in questionnaires where only positive responses were
marked (ie, GP only gave a response for cases where
he/she would prescribe) and it was therefore assumed
that the missing values were negative responses (ie, GP
would not prescribe for that case). A sensitivity analysis
was conducted to check this assumption by excluding
the surveys with missing values. The pattern of results
did not change.
RESULTS
Response rate
Over the four general practice conferences, we had a
30% response rate for surveys that were handed out at a
stall (90 surveys completed from 304 distributed at two
conferences) and a 3% response rate for surveys that
were inserted into GPs’ conference packs (55 surveys
completed from 1803 surveys inserted into GPs’ confer-
ence packs at three conferences). One returned survey
was excluded due to participant ineligibility (not cur-
rently practicing). A total of 144 GPs participated in this
study.
GP characteristics
The median age of the GPs who participated in the
study was 53 (IQR=47–59) and 58% were women. They
had been practicing medicine for a median of 28 years
(IQR=21–35) with a median practice size of ﬁve GPs
(IQR=3–8). Figure 1 shows GPs’ self-reported use of
absolute risk in their usual practice and the cases.
Prescription of blood pressure lowering medication
For cases in the high blood pressure group (SBP
≥147 mmHg) GPs stated that they would prescribe blood
pressure medication for 93% (95% CI 86% to 96%) of the
cases with high absolute risk (5-year risk of a CVD event
>15%) and 83% (95% CI 76% to 88%) of the cases with
lower absolute risk (see ﬁgure 2I and online supplemen-
tary appendix 1, Ai and B). Conversely, 30% (95% CI 25%
to 36%) of cases in the lower blood pressure group were
prescribed blood pressure medication if absolute risk was
high and 4% (95% CI 3% to 5%) of the cases if absolute
risk was lower (see ﬁgure 2I and online supplementary
appendix 1C and D).
Prescription of cholesterol lowering medication
GPs stated they would prescribe cholesterol medication
for 69% of cases with high cholesterol (TC/HDL ratio
≥6.5) and high absolute risk (95% CI 61% to 77%;
Table 1 The levels for absolute risk and individual risk factors blood pressure (SBP) and cholesterol (TC/HDL ratio) plus the
relevant case numbers and number of cases (n=144 GPs)*
Category figure 2/online
supplementary appendix 1 Absolute risk
Individual risk factors‡
SBP (mm Hg) TC/HDL ratio (mmol/L) N Case numbers
Ai Lower High Lower 431 25–35
Aii Lower Lower High 415 13–24
B† High High High 221 7–12
C† High Lower Lower 298 36–43
D Lower Lower Lower 219 1–6
*See online supplementary appendix 1 for the actual values used in these cases.
†Only the sets of cases B and C were eligible for treatment with cholesterol and blood pressure lowering medication according to the
Australian absolute risk guidelines10 11
GPS, general practitioners’; SBP, systolic blood pressure; TC/HDL, total cholesterol/high-density lipoprotein.
Figure 1 Self-reported use of absolute risk in practice and in
the cases (n=144 general practitioners).
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ﬁgure 2II, B). In contrast, a smaller percentage of cases
with high cholesterol but lower absolute risk were pre-
scribed cholesterol medication (34%, 95% CI 28% to
41%; ﬁgure 2II and see online supplementary appendix
1 Aii). The prescribing pattern for cholesterol medica-
tion in cases with lower cholesterol was similar to blood
pressure medication. GPs indicated that they would pre-
scribe cholesterol medication in just over a third of cases
(36%, 95% CI 30% to 43%; ﬁgure 2II and see online
supplementary appendix 1C) if absolute risk was high
and 10% of cases if absolute risk was lower (95% CI 8%
to 13%; ﬁgure 2II and see online supplementary appen-
dix 1D).
Prescription and patients’ characteristics
There were no differences in the pattern of prescribing
cholesterol medication for cases of different age groups
at similar risk (p=0.331). However, 61-year-old cases were
twice as likely (OR=2.00, p<0.001, 95% CI 1.52 to 2.65)
to be prescribed blood pressure medication than
72-year-old cases with the same risk proﬁle. GPs were
also more likely to indicate that they would prescribe
cholesterol medication (OR=1.27, p=0.025, 95% CI 1.03
to 1.56) but not blood pressure medication for male
cases (OR=1.24, p=0.212, 95% CI 0.89 to 1.72). Smoking
status was not associated with the prescription of choles-
terol or blood pressure medication (OR=0.66, p=0.077,
95% CI 0.42 to 1.05).
Prescription and GP characteristics
Older GPs were less likely to prescribe cholesterol medi-
cation (OR=0.77, p=0.039, 95% CI 0.60 to 0.99, per
10 years of age). A similar trend was found for years of
practice (OR=0.80, p=0.052, 95% CI 0.65 to 1.00, per
10 years of practice). GP age and years of practice were
not associated with stated prescribing of blood pressure
medication (OR=0.81, p=0.160, 95% CI 0.61 to 1.09, per
10 years of age; OR=0.84, p=0.191, 95% CI 0.65 to 1.09,
per 10 years of practice).
Stated prescribing was not signiﬁcantly associated with
self-reported use of the absolute risk approach in prac-
tice or GP gender. However, GPs who reported using
absolute risk in the cases were more likely to prescribe
blood pressure and cholesterol medication for cases with
high absolute risk (blood pressure medication: OR=1.29,
p=0.042, 95% CI 1.01 to 1.64; cholesterol medication:
OR=1.61, p=0.001, 95% CI 1.22 to 2.12). For the cases
with lower absolute risk these GPs also prescribed more,
but this was not statistically signiﬁcant (blood pressure
medication: OR=1.07, p=0.654, 95% CI 0.81 to 1.41;
cholesterol medication: OR=1.22, p=0.077, 95% CI 0.98
to 1.52).
DISCUSSION
Our analysis of the prescribing decisions for 144 GPs
over a range of systematically varied cases suggests that
GPs focus more on the levels of individual CVD risk
factors blood pressure and cholesterol than on absolute
risk, especially when prescribing blood pressure lowering
medication. The results suggest that, inconsistent with
the Australian guidelines,10 11 GPs are likely to prescribe
blood pressure and cholesterol lowering medication to
lower risk patients (5-year risk of CVD event <15%) if
these risk factors are elevated, even when an absolute
risk assessment is speciﬁcally provided to GPs.
Conversely, GPs did not always prescribe medication to
higher risk cases when blood pressure or cholesterol
were not elevated. These results are in line with our
hypotheses, and previous studies of patient records
showing overtreatment of low-risk patients and under-
treatment of high-risk patients, and that individual risk
factors inﬂuence prescribing.26–28 31–33 Age appeared to
Figure 2 Percentages of cases in which the general practitioners would prescribe a blood pressure or cholesterol lowering
drugs according to different combination of absolute (horizontal axis) and individual risk factors (vertical axis). The error bars
represent the 95% CIs for the percentage of cases (controlled for clustering). (Ai) High IR/lower AR with high individual risk
factors (blood pressure only) and lower absolute risk. (Aii) High IR/lower AR with high individual risk factors (cholesterol only) and
lower absolute risk. (B) High IR/high AR with high individual risk factors and high absolute risk*, (C) Lower IR/high AR with lower
individual risk factors and high absolute risk*, and (D) Lower IR/lower AR with lower individual risk factors and lower absolute
risk.
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be largely ignored as a risk factor, and GPs prescribed
less blood pressure lowering medication for 72-year-old
cases in comparison with 61-year-olds despite similar
descriptions in the scenarios (a relatively healthy ﬁt x
year old). This ﬁnding is worthy of further exploration,
given that age is one of the strongest risk factors for
CVD, as it runs counter to the concept of absolute CVD
risk and proposals based solely on an age cut-off.34 35 We
acknowledge that in clinical practice GPs may have
various and valid reasons for deviating from the guide-
lines, and strict adherence to guidelines and/or treat-
ment thresholds may undermine the shared
decision-making (SDM) approach that is now consid-
ered gold standard.36 37 SDM in the current context
would entail that a GP assesses absolute CVD risk,
explains this and the recommended management
approach to the patient, discusses the beneﬁts and
harms of the different management options with the
patient, and makes a shared decision with the patient.
Our study and previous work suggests that many GPs do
not base their recommendations on absolute risk, so it is
unlikely that they can adequately inform their patients
about the beneﬁts and harms of CVD risk management
and engage them in SDM.
Prescribing patterns were different for cholesterol and
blood pressure medication. Although explanatory
factors were not investigated in this study, historically,
antihypertensive prescribing dates back to the late
1950s; hypertension was the ﬁrst major CVD risk factor
successfully treated.38 In contrast, there was controversy
over the treatment of cholesterol until the large-scale
trials of statins reported in the mid-1990s,39 which coin-
cided with the emergence of ideas and methods using
absolute CVD risk. This history may have inﬂuenced the
language used for these risk factors; ‘hypertension’ is
more commonly used than its lipid analogues such as
‘hypercholesterolaemia’.
The strengths of this study include the heterogeneity
of the GPs who participated, and the systematic variation
of cases, but there are also some limitations: First, the
response rate was disappointing though typical for such
GP studies.27 However, any bias in our sample is likely to
favour GPs more interested and positive about absolute
risk, although almost 15% of GPs in our study stated
that they never use absolute risk in practice. Second, to
keep cases simple and clear we were restrictive in the
range of clinical variables and management options pre-
sented, excluding lifestyle modiﬁcation although space
was provided for comments. Third, we relied solely on
self-reported intentions to prescribe in the different
cases rather than actual prescribing behaviour. This
allowed an experimental design, but the results may not
reﬂect what is actually happening in clinical practice.
However, our results are likely to be an over-estimate of
the use of absolute risk in actual practice as the cases
explicitly provided GPs with an absolute risk score. We
know from our qualitative work that absolute risk is
often not assessed in practice.19
In conclusion, GPs’ decision-making was more consist-
ent with an individual risk factor approach than absolute
risk, especially when prescribing blood pressure lowering
medication. While more research to explore the cogni-
tions behind these reported behaviours would be worth-
while, our study identiﬁes a clear need to improve
guideline recommendations about how GPs should inte-
grate individual risk factor assessment with a manage-
ment that is guided by absolute CVD risk.
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